Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pharmalgen Vespula spp.
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
Pharmalgen Vespula spp. (brand name: Pharmalgen Wasp Venom) is a biologic allergen immunotherapy product manufactured by ALK-Abelló. Its active ingredient is partially purified, freeze-dried Vespula spp. (wasp/yellow jacket) venom, formulated as a powder and solvent for solution for injection. It is indicated for both the diagnosis (via skin testing) and treatment (via subcutaneous venom immunotherapy) of IgE-mediated allergy to wasp venom (insect venom hypersensitivity). The therapy works by desensitizing patients to wasp venom allergens, thereby preventing or reducing the severity of future systemic allergic reactions. It must be administered under medical supervision in a clinical setting equipped for cardiopulmonary resuscitation due to the risk of severe systemic allergic reactions.
- Brand names
- Pharmalgen Wasp VenomPharmalgen Yellow Jacket VenomPharmalgen
- Other names
- Vespula spp. venomvespula spp. venom protein extractwasp venom extractyellow jacket venom extractyellow jacket venom protein
02
Targets
FCER1 (Fc epsilon RI receptor)Venom-specific T-cell receptor / peptide-MHC class II recognition axis on CD4+ T cells
Beyond the preview
Go deeper on Pharmalgen Vespula spp..
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmalgen Vespula spp..